SCI-160

SCI-160 is an innovative, proprietary synthetic cannabinoid formulation developed for the treatment of pain. It acts as a selective agonist of the cannabinoid receptor type 2 (CB2), which is primarily expressed in peripheral tissues and immune cells. Unlike CB1 agonists, CB2-specific agonists like SCI-160 do not produce psychotropic effects. The active compound in SCI-160 was synthesized by Professor Raphael Mechoulam and is protected under patents in the US and Europe. Preclinical studies have demonstrated that SCI-160 significantly alleviates both acute and chronic pain, with efficacy comparable to or greater than high-dose morphine but without significant side effects or adverse clinical effects. The analgesic effect of SCI-160 is enhanced when combined with palmitoylethanolamide (PEA), a lipid molecule known for its anti-inflammatory and analgesic properties[1][4][5][6][7][9][10].

Other names

SCI 160SCI160SCI-160THX 160THX160THX-160